Bernstein’s view: Mazdutide, IBI363, and other oncology and broader biopharmaceutical pipeline assets are expected to drive Innovent’s product sales in China to approximately CNY 350 yi by 2030 and approximately CNY 520 yi by 2033. Conditions: sales of key products fall below forecasts, pipeline clinical failures occur, or launch timelines are significantly delayed.
Institutional views and platform commentary are distinguished. Archiving is not a report update. Original files remain private and are not available for download.
Bernstein’s view: Mazdutide, IBI363, and other oncology and broader biopharmaceutical pipeline assets are expected to drive Innovent’s product sales in China to approximately CNY 350 yi by 2030 and approximately CNY 520 yi by 2033. Conditions: sales of key products fall below forecasts, pipeline clinical failures occur, or launch timelines are significantly delayed.